A middle-aged man with short light brown hair, wearing round glasses, a striped shirt, and a gray blazer, smiles slightly while standing in a bright, blurred indoor setting.

Christoph U. Correll, MD

Department of Psychiatry, Zucker Hillside Hospital, Glen Oaks, New York; Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/ Northwell, Hempstead, New York; Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin, Berlin, Germany; German Center for Mental Health (DZPG), partner site Berlin, Berlin, Germany

JCP
Academic Highlights

June 30, 2020

In this journal CME activity, find experts' recommendations for reducing schizophrenia relapse, such as adopting a patient-centered approach, selecting medications based on current evidence, and implementing psychosocial interventions.
,
JCP
Letter to the Editor

June 16, 2020

Drs Kane and Correll reply to the letter "Depression as a Factor in Nonadherence in Schizophrenia" by Hirakawa and Ishii.
,
JCP
Consensus Statement

May 19, 2020

The quantification of antipsychotic levels in blood, or therapeutic drug monitoring (TDM), could aid clinicians in numerous challenging scenarios. Learn more about using TDM for dosing decisions in this...
, , , et al
JCP
ASCP Corner

April 28, 2020

Antipsychotic polypharmacy in schizophrenia is common, but is it supported by evidence? And why is there an apparent disconnect between efficacy and effectiveness? This ASCP Corner article considers those...
,
JCP
Educational Activity

April 14, 2020

Patient-reported outcomes are important for assessing the impact of schizophrenia and the success of treatment. Dr Correll discusses patient-centered care.
JCP
Educational Activity

April 14, 2020

New treatments for schizophrenia may improve symptom domains other than positive symptoms and reduce adverse effects. Here, an expert summarizes data on approved and investigational agents.
JCP
Original Research

March 17, 2020

People with psychotic disorders are more likely to have alcohol use disorder than the general population, but how does that comorbidity affect the course of their psychosis? This analysis...
, , , et al
JCP
Original Research

March 10, 2020

Alcohol use disorder is comorbid in 33% of US patients with schizophrenia. Testing the tolerability of olanzapine and samidorphan until the first event of exacerbation of disease symptoms is...
, , , et al
JCP
Academic Highlights

September 17, 2019

Long-acting injectable antipsychotics can be a powerful strategy in helping patients to receive ongoing benefit from treatment. You might think that you have adequately explained this treatment option to...
,
JCP
Review Article

July 16, 2019

Transdermal delivery is an alternative to oral routes of drug administration. This delivery route has several innate advantages that may benefit patients with CNS disorders—read this Expert Commentary to...
, ,
JCP
Original Research

April 23, 2019

Read a study examining if patients in the early phase of schizophrenia would accept LAI antipsychotic treatment.
, , , et al
JCP
Commentary

March 5, 2019

Read expert commentary on guidelines for treatment-resistant schizophrenia (TRS) to make more informed treatment decisions.
, , , et al

Consensus Report on XT Use in Practice

Read the full report
Figure: Graphic promoting Consensus Report on Xanomeline-Trospium; colorful net design shown with JCP logo in lower left.

Subscribe to read
more articles

Subscribe